Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...

A text allegedly sent by a young New Zealander accused of trying to bring 20kg of cocaine into Australia from the US has been aired in court. James Niven Timothy Moa, 21, was arrested at Sydney ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

The approval of trastuzumab in 1998 has significantly improved patients’ outcomes and paved the way for the beginning of advent of targeted approaches in breast cancer treatment. However, primary or ...

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...